Mainstay Medical International plc, an Irish company whose securities are listed on the regulated market of Euronext Paris and on the Euronext Growth market in Dublin, announced on 5 June the completion of an Irish scheme of arrangement procedure under which Mainstay Medical's shareholders received one share of a new unlisted Irish holding company. The completion of the transaction is followed by the delisting of the company's shares from Euronext Paris and Euronext Growth in Dublin with effect on June 8, 2020.
Mainstay is a European medical device company focused on bringing to market an innovative implantable neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain.
Latham & Watkins advised Mainstay Medical International plc on this transaction with a Paris team led by partner Pierre-Louis Cléro and counsel Semih Bayar Eren, assisted by Philippe Tesson on corporate aspects. Partner Xavier Renard assisted by Clémence Morel, advised on the tax aspects.